Circulating miR-145 as a marker of therapeutic response to anti-TNF therapy in patients with ankylosing spondylitis

Klára Prajzlerová \(^1\), Martin Komarc \(^3\), Šárka Forejtová \(^1,2\), Karel Pavelka \(^1,2\), Jiří Vencovský \(^1,2\), Ladislav Šenolt \(^1,2\), Mária Filková \(^1,2\)

\(^1\)Institute of Rheumatology, Prague, Czech Republic

\(^2\)Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic

\(^3\)Department of Anthropometrics and Methodology, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic.

Corresponding author:

Klára Prajzlerová

Institute of Rheumatology

Na Slupi 4, 128 00 Prague, Czech Republic

Email: prajzlerova@revma.cz

Short title: Circulating miR-145 in ankylosing spondylitis
Summary

Circulating miRNAs appear promising therapeutic and prognostic biomarkers. We aimed to investigate the predictive value of circulating miRNAs on the disease outcome following anti-TNF therapy in patients with ankylosing spondylitis (AS). Our study included 19 AS patients assessed at baseline (M0), after three (M3) and twelve months (M12) of anti-TNF therapy. Total RNA was isolated from plasma. A comprehensive analysis of 380 miRNAs performed using TaqMan Low Density Array (TLDA) was followed by a single assay validation of selected miRNAs. All AS patients had high baseline disease activity and a good/excellent response to anti-TNF therapy at M3 and M12. TLDA analysis revealed the dysregulation of 17 circulating miRNAs, including miR-145. Single assay validation confirmed that miR-145 is significantly downregulated at M3 compared to baseline. The decrease in the levels of miR-145 from M0 to M3 negatively correlated with the change in BASDAI from M0 to M3; however, it and positively correlated with disease activity improvement from M3 to M12 as per BASDAI and ASDAS. The predictive value of the early change in miR-145 as well as and levels of miR-145 at M3 was further validated by ROC Receiver operating curves analysis.

We show that the early change in circulating miR-145 may be a predictor for the future outcome of AS patients treated with TNF inhibitors. Patients with a more significant decrease in miR-145 levels associated with less initial improvement in BASDAI may show further significant improvement of disease activity after 12 months. Monitoring of the expression of miR-145 in plasma in AS patients may, therefore, influence our therapeutic decision-making.

Keywords: miRNA, ankylosing spondylitis, anti-TNF therapy, biomarker
Introduction

Ankylosing spondylitis (AS) is a chronic inflammatory disease that mainly affects the axial skeleton and typically presents with inflammatory back pain (Taurog et al., 2016). Inflammatory back pain, reduced mobility of the spine, and radiographic evidence of sacroiliitis are all part of the modified New York diagnostic criteria for AS (van der Linden et al., 1984). The new ASAS (The Assessment of SpondyloArthritis International Society) classification criteria for axial spondyloarthritis (AxSpA) use magnetic resonance imaging (MRI) of sacroiliac joints to detect spinal inflammation in patients with the non-radiographic stage of the disease and to enable earlier diagnosis (Rudwaleit et al., 2009). The most widely used tool for measuring disease activity of patients with AS is the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) that reflects the disease activity from the patient’s perspective (Garrett et al., 1994). Later, the ASDAS (Ankylosing Spondylitis Disease Activity Score) for the assessment of disease activity was developed (Lukas et al., 2009). This includes C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) as laboratory markers of disease activity. The worsening of spinal mobility is influenced by inflammation in the early disease and by structural damage in the radiographic phase (Machado et al., 2010). The first evidence of a good treatment response to anti-TNF (tumor necrosis factor) agents in patients with AS was described almost 20 years ago (Brandt et al., 2000). Current data suggest that the early initiation of therapy may reduce the radiographic progression in AS (Haroon et al., 2013). Significant improvement of disease activity, functional outcomes and inhibition of radiographic progression have been shown in patients treated with anti-TNF biologic drugs (Taurog et al., 2016).

There are several biomarkers of activity or treatment response being tested in AxSpA, but more studies in large patient cohorts are needed for their implementation in the clinical practice (Prajzlerova et al., 2016, Prajzlerova et al., 2017). CRP remains the best circulating
marker for assessing disease activity and for predicting treatment response and structural progression (Prajzlerova et al., 2016). MicroRNA (miRNAs) are small, non-coding RNAs important for post-transcriptional regulation of gene expression. Moreover, cell-free circulating miRNAs are released from the cells, are stable in body fluids, and may serve as promising therapeutic and prognostic biomarkers, e.g., in rheumatoid arthritis or AxSpA, or other non-rheumatic diseases (Filkova et al., 2014, Hruskova et al., 2016, Prajzlerova et al., 2017, Dlouha and Hubacek, 2017). We have previously presented circulating miRNAs as markers of spinal involvement and disease activity in patients with AxSpA (Prajzlerova et al., 2017). The aim of the current study was to investigate miRNAs as predictors of treatment response to anti-TNF therapy in patients with AS.
Methods

Patients

This study included 19 patients who fulfilled the New York classification criteria for AS (van der Linden et al., 1984). Three patients had radiographic sacroiliitis, two stage I AS, 2 had lumbar syndesmophytes, four stage II AS, 4 had thoracic syndesmophytes, stage III AS, 9 had stage IV AS, and ten had cervical bamboo spine involvement as described earlier—stage V AS (Braun et al., 2002). All patients commenced treatment with anti-TNF therapy: six received infliximab, five etanercept, five adalimumab, 5 golimumab, and three were treated with adalimumab etanercept. Clinical and laboratory parameters of disease activity were assessed using BASDAI (Garrett et al., 1994), ASDAS-CRP (Lukas et al., 2009), ESR and CRP at baseline (M0) prior to the start of treatment and after three (M3) and twelve months (M12) of therapy. Clinical characteristic is provided in Table 1. Patients were recruited from the outpatient clinic of the Institute of Rheumatology in Prague. Written informed consent was obtained from all participants prior to enrolment. The study was approved by the local Ethics committee at the Institute of Rheumatology in Prague.

Samples and RNA isolation

Whole blood samples collected in EDTA tubes were obtained from all participants at baseline, at M3 and M12 of therapy. Plasma was separated by centrifugation within four hours of collection, ensuring constant pre-analytical conditions for all samples. All plasma samples were stored at -80°C and no freeze-thaw cycles occurred before use. Total RNA, including the miRNA fraction, was extracted from plasma samples (100μl) using miRNeasy Serum/Plasma Kit (Qiagen, Düsseldorf, Germany) according to manufacturer’s instructions. Spike-in non-human synthetic miRNA (C. elegans cel-miR-36, cel-miR-54, and cel-miR-238) were added to the
samples after the initial denaturation for further normalization. Total RNA was eluted in 24μl of RNase-free water and stored at -80°C. Total RNA concentration was measured using a NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) in all samples.

miRNA expression analysis

First, non-pooled individual plasma RNA samples (M0, M3, and M12 from randomly selected three patients) were used. Complementary DNA was obtained by reverse transcription using a TaqMan® MicroRNA Reverse Transcription Kit with Megaplex RT Primers (Thermo Fisher Scientific) with equal RNA input. cDNA was preamplified using 2x TaqMan® PreAmp Master Mix and Megaplex™ PreAmp Primers (all Thermo Fisher Scientific) on a PCR thermocycler (Bio-Rad Laboratories, Hercules, CA, USA). The expression of 380 miRNAs was measured using Human Pool A TaqMan® Low Density Array (TLDA) platforms for microRNAs on QuantStudio 7Flex Real-Time PCR System (Thermo Fisher Scientific). All steps were performed according to the manufacturer’s instructions. The dCt method was used for relative quantification as follows: dCt=Ct(array average)-Ct(miRNA of interest), followed by x-fold change calculations.

For further single assay validation, total RNA from 19 non-pooled samples was reverse-transcribed using TaqMan Real Time miRNA specific primers (including cel-miR-39, cel-miR-54, and cel-miR-238) and then amplified by real-time PCR with TaqMan probes and TaqMan Universal PCR Master Mix on QuantStudio 7 Flex Real-Time PCR System (all Thermo Fisher Scientific). The dCt method was used for relative quantification as follows: dCt=Ct(spike-in average)-Ct(miRNA of interest); higher dCt values represent the higher expression of particular miRNAs. All data were analyzed with QuantStudio 7 Flex Real-Time PCR System Software (Thermo Fisher Scientific).
ELISA

The levels of VEGF in plasma were measured using a commercially available ELISA kit (Human VEGF Quantikine ELISA, R&D systems, Inc., Minneapolis, MN) according to the manufacturer’s protocol. Absorbance was quantified using a Sunrise ELISA reader (Tecan Group Ltd., Zürich, Switzerland) with 450 nm as the primary wavelength, and the data were analysed using Kim version 5.43.01 software (Daniel Kittrich – Software Production, Prague, Czech Republic).

Statistical analysis

The normality assumption was assessed using the Shapiro-Wilk test. Data are presented as the median with interquartile range (IQR). ANOVA with Bonferroni corrections, Spearman’s correlation coefficient, Receiver operating curves (ROC), Area under the curve (AUC), and Fisher’s exact test were used. P values less than 0.05 were considered statistically significant. All analyses and graphs were performed using GraphPad Prism 5.02 (GraphPad Software, La Jolla, CA, USA).
Results

Clinical characteristic and treatment response

All AS patients had high disease activity prior to commencing the anti-TNF therapy (BASDAI > 4 and abnormal CRP) with a good therapeutic response at M3 and M12 based on CRP, ESR, BASDAI, and ASDAS (Table 1). All these parameters decreased significantly from M0 to M3 (p<0.001 for all comparisons) and remained significantly low at M12 (p<0.001 for all comparisons). As expected, there were no significant differences between M3 and M12 in any monitored parameters of disease activity (p>0.05 for all comparisons).

Analysis of miRNAs

A comprehensive analysis of 380 circulating miRNAs in three patients was performed using TLDA, as described above. Out of the 380 miRNAs, 125 miRNAs were detected in all samples, while 148 miRNAs were detected at M0, 154 at M3, and 151 at M12. Only miRNAs expressed consistently in all 49 samples below Ct cycle 30 and showing >1.5-fold change between at least two groups in initial analysis were taken for further validation (17 miRNAs in total). Single assay validation confirmed any difference between groups in the expression of nine miRNAs (Thermo Fisher Scientific Assay Name: miR-16, miR-26b, miR-29a, miR-140, miR-142-3p, miR-145, miR-150, miR-192, miR-374). However, only miR-145 (miRBase ID: has-miR-145-5p) showed significant changes from baseline to M3.

Given our interest in the predictive value of baseline or early change in miRNA expression for future outcomes in AS patients, only miR-145 was taken for further extended analysis. TLDA analysis of three samples revealed lower levels of circulating miR-145 at M3 (1.59-fold) and M12 (1.46-fold) compared to baseline (Figure 1A). Next, single assay validation in 19 samples confirmed 1.62-fold lower expression of miR-145 at M3 compared
to baseline (p=0.024), but there were no significant differences after 12 months of therapy (p>0.05) (Figure 1B).

**Early change in the expression of circulating miR-145 as a predictor of future outcome**

The decrease in the levels of miR-145 from M0 to M3 in plasma is negatively associated with the change in BASDAI from M0 to M3 (p=0.041; r=-0.472) (Figure 2): the more significant decrease in miR-145 levels, the less improvement in BASDAI (Δ BASDAI).

The disease outcome at M12 proved that the decrease in the miR-145 levels from M0 to M3 significantly positively correlated with disease activity improvement over time from M3 to M12 as per BASDAI (p=0.002; r=0.672) and ASDAS (p=0.006; r=0.607) (Figure 3A). Therefore, patients with a more significant decrease in miR-145 levels associated with less initial improvement in BASDAI until M3 may show further significant improvement of BASDAI (and ASDAS) at M12. Importantly, this hypothesis was further confirmed by ROC analysis. The ROC curves showed that the decrease in the miR-145 expression from M0 to M3 predicts the disease activity improvement from M3 to M12 defined by BASDAI (AUC [95%CI] 0.807 [0.593 to 1.0], p=0.026), but not by ASDAS (AUC [95%CI] 0.601 [0.439 to 0.925], p=0.186) (Figure 3B).

Furthermore, there was a positive correlation between the levels of miR-145 at M3 and disease outcome at M12: the lower levels of miR-145 at M3, the more improvement of disease activity from M3 to M12 and disease activity at M12 assessed by both BASDAI (Δ BASDAI: p=0.063; r=0.435 and BASDAI: p=0.071; r=0.423) and ASDAS (Δ ASDAS: p=0.007; r=0.593 and ASDAS: p=0.019; r=0.533) (Figure 4A). ROC analysis confirmed, that plasma levels of miR-145 at M3 significantly predicted low disease activity at M12 defined by BASDAI (cut off 4) (AUC [95% CI] 0.896 [0.703 to 1.0]; p=0.034) and ASDAS (cut of
2.1) (AUC [95% CI] 0.810 [0.564 to 1.0]; p=0.028) (Figure 4B), nevertheless it did not predict remission defined by ASDAS (cut off 1.3) (data not shown).

Overall, as shown in Figure 1, there was no significant change in miR-145 levels from M3 to M12. However, the plasma expression of miR-145 increased from M3 to M12 in 10 patients (p<0.001). In comparison to the remaining nine patients whose miR-145 expression decreased from M3 to M12 (p=0.004), these patients had significantly lower levels of miR-145 at M0 (p=0.044) and M3 (p=0.002), although the levels of miR-145 at M12 were comparable (p=0.164). Moreover, these patients had lower ASDAS at M0 (p=0.028), M3 (p=0.006), and M12 (p=0.010) and CRP at M12 (p=0.043), but there were no differences in BASDAI at any time (data not shown). There were no differences secondary to the biological agents used or between patients treated with monoclonal antibodies and etanercept (p>0.05).

In the first group with increasing levels of miR-145 from M3 to M12, 7 patients were treated with monoclonal antibodies (2 with adalimumab, 4 with golimumab, and 1 with infliximab) and the remaining 3 with etanercept. In the second group, 7 patients were treated with monoclonal antibodies (1 with adalimumab, 1 with golimumab, and 5 with infliximab), and 2 were treated with etanercept.

VEGF and association with circulating miR-145 and treatment response

As VEGF was shown as a direct target of miR-145 (Fan et al., 2012), we were interested in its association with circulating miR-145 in plasma. There was a trend towards the decrease in VEGF levels from M0 to M3 (p=0.069), but there was no further change at M12 compared to M3. Baseline Levels of VEGF do not correlate with disease activity, or its change at any time; however, the decrease in VEGF from M0 to M3 correlated with decreased CRP (p=0.001;
r=0.733) and ESR (p=0.023; r=0.517) from M0 to M3. There was no correlation between the levels of VEGF and miR-145 at any time (p>0.1 for all comparisons) (data not shown).
Discussion

MicroRNAs are essential regulators of gene expression and therefore contribute to the physiology in health as well as to the pathophysiology of diseases, including inflammatory conditions (Filкова et al., 2012). Circulating miRNAs were shown to be very stable and easily accessible that makes them potential biomarkers (Cortez et al., 2011). Circulating miRNAs miR-23a-3p and miR-223-3p were previously described as biomarkers of therapeutic response to anti-TNF treatment in RA patients (Castro-Villegas et al., 2015). Regarding individuals with AS treated with anti-TNF therapy, however, there are only a few studies available related to miRNAs (Lv et al., 2015). Recently, circulating miR-5196 was shown to be decreased after anti-TNF therapy in AS patients, and change in the expression of miR-5196 correlated with disease activity improvement after therapy treatment (Ciechomska et al., 2018). However, other studies on circulating miRNAs as markers of therapeutic response are lacking.

We analyzed the effect of anti-TNF therapy in AS patients on the expression of a wide range of circulating miRNAs. From the comprehensive analysis of miRNAs isolated from plasma, 17 miRNAs of a minimum 1.5-fold change difference were selected for further validation. From selected miRNAs, only miR-145 revealed a significant decrease from baseline to month three. There was still a significant decrease at month 12 in comparison to baseline, but there was no difference compared to month three.

Next, we validated the pilot data and assessed the relationship between miR-145 and the disease activity and treatment response in a larger patient cohort. We confirmed the decrease of miR-145 from baseline to M3 but no change from M3 to M12. We found that the more significant decrease in miR-145 expression correlated with poorer improvement of disease activity during the first three months. Importantly, our data showed that patients with a more significant reduction in miR-145 levels that is associated with the little improvement in
BASDAI until month 3 may develop further significant improvement and better disease outcomes after 12 months of therapy based on BASDAI and ASDAS. The assessment of treatment response to anti-TNF therapy assessed treatment after three3 months is essential for further treatment decision making: whether the switch is indicated or the patient remains on the same drug. In this context, our data showed that patients with the more significant decrease in miR-145 levels that associated with the little improvement in BASDAI until month three may develop further significant improvement and better disease outcome after 12 months of therapy based on BASDAI and ASDAS. We therefore showed that the therapeutic switch at threeBased on our miR-145 data, we propose that the therapeutic switch after 3 months would be premature as some patients will improve significantly after 12 months on the same therapy.

We hypothesized a potential link between circulating miR-145 (and its reflection of disease outcome) in our AS patients with its possible involvement in the pathogenesis of AS. MiR-145 is known mainly as a tumor suppressor that mediates cell growth, invasion, and metastasis (Sachdeva and Mo, 2010)—MiR-145 inhibited activation of AKT and ERK1/2 pathway by targeting oncogene N-RAS and IRS1. Also, AKT and ERK1/2 are regulators of VEGF and their inhibition in colorectal cancer cells resulted in significant downregulation of VEGF. VEGF was also described as a direct target gene of miR-145 since the overexpression of miR-145 downregulated VEGF expression in osteosarcoma cells. Next, in vivo overexpression of miR-145 decreased cell proliferation, migration, invasion and VEGF secretion in thyroid cancer. VEGF is a crucial mediator in angiogenesis, is involved in osteogenesis and therefore also in bone remodelling. VEGF was shown to be increased in patients with AS in comparison with healthy controls and decreased following anti-TNF therapy (Pedersen et al., 2010).—Given these data on miR-145 and VEGF is a crucial mediator in angiogenesis, is
involved in osteogenesis, and, therefore, bone remodeling (Hu and Olsen, 2016) and was previously described as a direct target gene of miR-145 (Fan et al., 2012) patients with AS. we hypothesized a promising association at the systemic level. We showed that expression of miR-145 decreased after the treatment with TNF inhibitors after three months. We, Although we proved the decrease in systemic VEGF after anti-TNF therapy as shown previously (Pedersen et al., 2010). However, we showed no associations between circulating miR-145 and VEGF. Nevertheless, there still may be a relationship between circulating miR-145 and VEGF at the site of

The characteristic inflammation that is of spondyloarthritis occurs at the interface between cartilage and bone in the sacroiliac joints, the spine, and the entheses. The mechanisms of interaction between inflammation, paradoxical bone destruction, and new bone formation are still not reflected systemically, or an association with other molecular aspects of completely understood. However, studies have suggested that the initial inflammation (in which TNF is the principal cytokine involved) causes erosions in cartilage and bone; these lesions are then filled in by fibrous tissue, that is later ossified, leading to abnormal bony growth (syndesmophytes, bone bridges, and complete ankyloses) (Sieper and Poddubnyy, 2017, Watad et al., 2018, Cici et al., 2019). Undoubtedly, the Wnt (Wingless) signaling pathway is considered one of the primary regulators of bone metabolism. It is involved in osteoblast differentiation from mesenchymal precursors and osteoprogenitor cells, osteoblast regulation, proliferation, and survival (Cici et al., 2019). Remodelling. MiR-145 was shown to negatively regulate chondrogenesis and bone formation (osteogenic differentiation, osteoblastogenesis or bone regeneration) at multiple levels of Wnt signaling and other bone-homeostasis related mechanisms (Jia et al., 2013, Yang et al., 2011, Hao et al., 2018, Fukuda et al., 2015) and to aggravate bone erosions by promoting osteoclastogenesis (Chen et al., 2018). We, therefore, suggest that our data may reflect the involvement of miR-145 in bone-remodeling in AS. In
In our previous work, we showed lower levels of miR-145 in plasma of AS patients than healthy controls and between non-radiographic AxSpA and advanced AS stages (Prajzlerova et al., 2017). On the other hand, miR-145 was also presented as an inhibitor of osteoclastogenesis induced by RANKL by regulation of Smad3. We hypothesize that the decrease in miR-145 levels in the first 3 months of anti-TNF therapy can reflect the shift from the initial erosive process to the induction of reparative mechanisms represented by new bone formation. In our study, these could be reflected by further improvement in BASDAI score during follow-up.

Despite presenting miR-145 as a predictor of future response to anti-TNF therapy, our study has some limitations. Firstly, our data show the association of miR-145 with a short-term disease outcome in advanced disease (most AS patients had cervical spine involvement). The predictive value of miR-145 for radiographic progression is missing and would need long-term follow up. Similarly, analysis of miR-145 in the non-radiographic disease would certainly undoubtedly be of interest as well, although our previous study showed no difference in miR-145 between healthy controls and non-radiographic AxSpA. Our data also need validation in larger patient cohorts. The data from published in vitro and in vivo studies show different roles of miR-145 in inflammation or bone formation. Our data are descriptive and show no association with selected mediators of inflammation or tissue remodelling (e.g., CRP or VEGF). We can only hypothesize the exact role of miR-145 in the pathogenesis of AS and, especially, which pathophysiologic aspect of TNF inhibition is reflected by changes in circulating miR-145 in patients with AS. This is, indeed, generally difficult. Although bone-remodeling appears suggestive, we are unable to show directly prove this as we didn’t look directly at the tissues of interest, and also, when circulating miRNAs are studied, they may originate from different cells or tissues and reflect various more or less specific tissue-related pathways.
To conclude, we show that the early change in circulating miR-145 may be a predictor for the future outcome of AS patients treated with anti-TNF inhibitors. Patients with the more significant decrease in miR-145 levels associated with the less initial improvement in BASDAI may show further significant improvement of disease activity after 12 months. Monitoring of the expression of miR-145 in plasma in AS patients may, therefore, influence our therapeutic decision-making.
Acknowledgments:

This work was supported by a grant 17-33127A of the Agency for Healthcare Research of the Czech Republic—\textit{and a project of the MHCR for conceptual research development No. 023728.}

There is no financial support or other benefits from commercial sources for the work reported in the manuscript.
References


Figure legends

**Figure 1** Plasma expression of miR-145 at baseline, month 3, and month 12 of anti-TNF therapy.

(A) Expression analyzed using comprehensive TaqMan Low Density array and (B) single assay validation. Data expressed as median with interquartile range. NS, not significant. *p≤0.05*  

\[ dCt = \text{Ct(array average)} - \text{Ct(miRNA of interest)} \]

Higher \( dCt \) values represent, therefore a higher expression of miR-145.

**Figure 2** Negative correlation between the change in miR-145 levels and BASDAI from month 0 to month 3.

\[ \Delta dCt \text{ miR-145 M0/M3 is calculated as M3-M0 (numbers <0 represent decreasing miRNA expression), } \Delta \text{ BASDAI M0/M3 is calculated as M3-M0 (numbers <0 represent the improvement of disease activity).} \]
Figure 3 Relationship between the early change in miR-145 expression from month 0 to month 3 and further clinical improvement from month 3 to 12.

(A) Correlation of decreasing in miR-145 expression from M0 to M3 with disease activity improvement from M3 to M12. (B) ROC curves analysis of the change in miR-145 expression from M0 to M3 as a predictor of disease activity improvement from M3 to M12 defined by BASDAI and ASDAS. \( \Delta \text{dCt miR-145 M0/M3} \) is calculated as \( M3-M0 \) (numbers <0 represent decreasing miRNA expression), \( \Delta \text{BASDAI} \) and \( \Delta \text{ASDAS M3/M12} \) are calculated as \( M12-M3 \) (numbers <0 represent the improvement of disease activity).
Figure 4 Relationship between the expression of miR-145 at month 3 and disease activity outcome at month 12.

(A) Correlation of expression of miR-145 at M3 with disease activity outcome at M12. (B) Receiver operator characteristic (ROC) curves analysis of expression of miR145 at M3 as a predictor for the low disease activity at M12 defined by BASDAI (<4) and ASDAS (<2.1). Δ BASDAI and Δ ASDAS are calculated as BASDAI/ASDAS M12-M3 (numbers <0 represent the improvement of disease activity).
Table legends

Table 1 Clinical characteristics of patients with ankylosing spondylitis

<table>
<thead>
<tr>
<th>Variable</th>
<th>M0</th>
<th>M3</th>
<th>M12</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A

B

miR-145 M3 vs. BASDAI M12

miR-145 M3 vs. ASDAS M12
<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender; Female/Male</td>
<td>6/13</td>
<td>-</td>
<td>-</td>
<td>NA</td>
</tr>
<tr>
<td>Age; years</td>
<td>38.16</td>
<td>-</td>
<td>-</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>[15.22]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HLA-B27 positivity; n (%)</td>
<td>19 (100%)</td>
<td>-</td>
<td>-</td>
<td>NA</td>
</tr>
<tr>
<td>CRP; mg/l</td>
<td>22.61</td>
<td>3.09 [8.01]</td>
<td>3.96 [5.70]</td>
<td>&lt;0.001&lt;sup&gt;a,b&lt;/sup&gt; NS&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>[29.47]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESR; mm/h</td>
<td>36 [26]</td>
<td>6 [18]</td>
<td>11 [23]</td>
<td>&lt;0.001&lt;sup&gt;a,b&lt;/sup&gt; NS&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>BASDAI</td>
<td>6.45 [3.05]</td>
<td>2.40 [1.92]</td>
<td>1.67 [1.40]</td>
<td>&lt;0.001&lt;sup&gt;a,b&lt;/sup&gt; NS&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>ASDAS-CRP</td>
<td>4.15 [0.93]</td>
<td>2.28 [0.92]</td>
<td>1.63 [0.84]</td>
<td>&lt;0.001&lt;sup&gt;a,b&lt;/sup&gt; NS&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Anti-TNF therapy; n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adalimumab</td>
<td>3 (16%)</td>
<td>-</td>
<td>-</td>
<td>NA</td>
</tr>
<tr>
<td>Infliximab</td>
<td>6 (32%)</td>
<td>-</td>
<td>-</td>
<td>NA</td>
</tr>
<tr>
<td>Golimumab</td>
<td>5 (26%)</td>
<td>-</td>
<td>-</td>
<td>NA</td>
</tr>
<tr>
<td>Etanercept</td>
<td>5 (26%)</td>
<td>-</td>
<td>-</td>
<td>NA</td>
</tr>
<tr>
<td>AS stage; n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage I</td>
<td>3 (16%)</td>
<td>-</td>
<td>-</td>
<td>NA</td>
</tr>
<tr>
<td>Stage II</td>
<td>2 (10%)</td>
<td>-</td>
<td>-</td>
<td>NA</td>
</tr>
<tr>
<td>Stage III</td>
<td>4 (21%)</td>
<td>-</td>
<td>-</td>
<td>NA</td>
</tr>
<tr>
<td>Stage IV</td>
<td>9 (48%)</td>
<td>-</td>
<td>-</td>
<td>NA</td>
</tr>
<tr>
<td>Stage V</td>
<td>1 (5%)</td>
<td>-</td>
<td>-</td>
<td>NA</td>
</tr>
</tbody>
</table>

Abbreviations: AS, ankylosing spondylitis; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity index; CRP, C-reactive
protein; ESR, Erythrocyte Sedimentation Rate; NA, not applicable; NS, not significant; Data are presented as a median and interquartile range [IQR]. a, comparison between M0 and M3; b, comparison between M0 and M12; c, comparison between M3 and M12.